ACTRN12619000859189尚未招募4 期
Efficacy and safety of Artesunate-amodiaquine for the treatment of uncomplicated Plasmodium falciparum and Plasmodium vivax malaria in Eritrea
Ministry of Health of Eritrea0 个研究点目标入组 704 人开始时间: 2019年6月17日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 704
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 6 Months 至 o limit(—)
- 性别
- All
入选标准
- •1.age between 6 months and above;
- •2.infection with P. falciparum or P. vivax a parasites confirmed by positive blood smear (no mixed infection);
- •3.parasitaemia of 250-200, 000 asexual forms per microliter;
- •4.presence of axillary or tympanic temperature greater or equal to 37.5 degree centigrade or history of fever during the past 24 h;
- •5.ability to swallow oral medication;
- •6.ability and willingness to comply with the study protocol for the duration of the study and to comply with the study follow-up visit schedule;
- •7.informed consent from the patient or from a parent or guardian in the case of children aged less than 18;
- •8.informed assent from any minor participant aged from 12 to 18 years; and
- •9.Consent for pregnancy testing from female of child-bearing age (defined as age > 12 years and sexually active) and from their parent or guardian if under the age of 18.
排除标准
- •1.presence of general danger signs in children aged under 12 years or signs of severe P. falciparum or P. vivax malaria according to the definitions of WHO;
- •2.weight under 5 kg;
- •3.haemoglobin < 8 g per deciliter;
- •4.presence of severe malnutrition defined as a child aged between 6-60 months whose weight-for-high is below –3 z-score, or has symmetrical oedema involving at least the feet or has a mid-upper arm circumference < 115 mm).
- •5.presence of febrile conditions due to diseases other than malaria (e.g. measles, acute lower respiratory tract infection, severe diarrhea with dehydration) or other known underlying chronic or severe diseases (e.g. cardiac, renal and hepatic diseases, HIV/AIDS);
- •6.regular medication, which may interfere with antimalarial pharmacokinetics;
- •7.history of hypersensitivity reactions or contraindications to any of the medicine(s) being tested or used as alternative treatment(s);
- •8.a positive pregnancy test or breastfeeding; and
- •9.unable to or unwilling to take pregnancy test or to use contraception for women of child-bearing age (defined as age above 12 years and sexually active).
研究者
相似试验
已完成
4 期
Efficacy and safety of artesunate-amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in West Sumba District, East Nusatenggara Province, IndonesiaInfection - Studies of infection and infectious agentsMalariaACTRN12611000999932Malaria sub-directorate, Directorate General of Disease control and Environmental Sanitation100
尚未招募
不适用
Efficacy and safety of artesunate-amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Kobeni (province of Hodh El Gharbi) and Timbedra (province of Echargui), MauritaniaACTRN12613000396729Ministry of Health Mauritania120
尚未招募
4 期
Safety and efficacy of artesunate-amodiaquine for the treatment of uncomplicated malaria in BurundiMalariaPACTR201905610589889Ministere de la Sante Publique352
尚未招募
4 期
Efficacy and safety of artesunate-amodiaquine and artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum in health units of the Agua Grande and Lobata districts of the Sao Tome Island, Sao Tome and PrincipeInfection - Studies of infection and infectious agentsMalariaACTRN12616001609448Ministry of Health of Sao Tome and Principe176
已完成
4 期
Efficacy and safety of artesunate-amodiaquine and artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Keur Soce, district of Ndoffane and Guediawaye, district of Guediawaye, Senegal.MalariaACTRN12610001023044Ministry of Health and Prevention of Senegal240
